Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 4/20 | 0.62 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.62 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.58 |
| ▸ | DGKA | P23743 | 1/20 | 0.45 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30633511 | 1.00 | LPAR1 (0.62) | LPAR1LPAR3ENPP2DGKANLRP3 | |
| SCHEMBL29651480 | 1.00 | LPAR1 (0.62) | LPAR1LPAR3ENPP2DGKANLRP3 | |
| SCHEMBL17320970 | 1.00 | LPAR1 (0.62) | LPAR1LPAR3ENPP2DGKANLRP3 | |
| SCHEMBL29372509 | 0.93 | LPAR1 (0.55) | LPAR1LPAR3ENPP2 | |
| SCHEMBL17482404 | 0.93 | LPAR1 (0.55) | LPAR1LPAR3ENPP2 | |
| SCHEMBL29651433 | 0.90 | LPAR1 (0.52) | LPAR1LPAR3 | |
| SCHEMBL21361188 | 0.84 | LPAR1 (0.47) | LPAR1LPAR3ENPP2 | |
| SCHEMBL9905967 | 0.83 | MGLL (0.45) | LPAR1LPAR3 | |
| SCHEMBL9905965 | 0.82 | ALDH1A1 (0.55) | — | |
| SCHEMBL471855 | 0.79 | LPAR1 (0.59) | LPAR1LPAR3ENPP2DGKANLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119959415-A | Screening method of quality markers of hemorrhoid treatment pills for treating hemorrhoid | 兰州佛慈制药股份有限公司 | 2025-05-09 | — | — | CN | disclosed |
| US-20150315216-A1 | PHOSPHATE COMPOSITION | VANTAGE SPECIALTIES, INC. | 2015-11-05 | — | — | US | disclosed |
| US-20150315216-A1 | PHOSPHATE COMPOSITION | VANTAGE SPECIALTIES, INC. | 2015-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315216-A1 | PHOSPHATE COMPOSITION | PHOSPHO1, PLA2G2C, PLCG2 | LPAR1 278/4885LPAR3 252/4885ENPP2 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.